Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

By J. Haanen, F. Carbonnel, C. Robert, K. Kerr, S. Peters, J. Larkin, K. Jordan. Annals of Oncology, 2017

740 citations recorded by the source corpus.

Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands; Department of Gastroenterology, Kremlin Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Department of Medicine, Dermatology Unit, Gustave Roussy Cancer Campus, Villejuif, France; Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary, Aberdeen, UK; Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Royal Marsden Hospital NHS Foundation Trust, London, UK; Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/194ac2232045256ca3b48d0a698a989707a5fd99

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. O. Michielin
2. A. V. Akkooi
3. R. Dummer
4. P. Ascierto
5. U. Keilholz

Citations in the corpus

• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Good references exist for immunotherapies [89] as well as for MAPK inhibitors [90].”